APC wins clinical trial material supply contract from Affymax
American Peptide Company (APC) has won a contract for the production of clinical trial quantities of Hematide, a synthetic peptide-based drug candidate, for California-based Affymax.
American Peptide Company (APC) has won a contract for the production of clinical trial quantities of Hematide, a synthetic peptide-based drug candidate, for California-based Affymax.
Hematide is designed to stimulate the production of red blood cells and is being evaluated by US-based Affymax in Phase II clinical trials to treat anemia in patients with chronic kidney disease and cancer.
APC, a wholly-owned subsidiary of Itoham Foods of Japan, has previously manufactured preclinical batches of Hematide for Affymax. It will manufacture clinical supplies of the drug at its large-scale cGMP manufacturing facility near San Diego, California.